ALS candidates from Biohaven, Prilenia, Clene and UCB have all failed to halt disease progression versus placebo in the US-wide platform trial.

All nine patients treated with a personalized cancer vaccine following removal of their tumors remained cancer-free at a median data cut-off of 34.7 months.

The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new ...

Shares of Septerna sank to their lowest level yet after the company said it would end the phase 1 clinical trial for SEP-786 as a treatment for hypoparathyroidism. The stock fell 68% to a low of $4.17 ...

Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory mechanisms, empowering genes that promote tumor growth in clear cell renal cell ...

Trial decision follows unanticipated events of elevated unconjugated bilirubin levelsCompany advancing multiple next-generation PTH1R agonists ...

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...

TG Therapeutics will use MaxCyte’s technology to advance toward a clinical trial its azer-cel CAR T-cell therapy for ...

TuHURA Biosciences, a biotech firm, is advancing DNA-based immunotherapy for cancer. Read what warrants a Hold rating for ...

Abstracts presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium reflect the ongoing ...

At the Envision Summit 2025 in San Juan, Puerto Rico, Deepak Sambhara, MD, gave insight into the 96-week post hoc fluid ...